Altheim, Germany

Melanie Briegel


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Melanie Briegel

Introduction

Melanie Briegel, an accomplished inventor based in Altheim, Germany, has made significant strides in the field of cell culture technology. With her expertise, she focuses on methods that enhance recloning efficiency, which is crucial for the production of biopharmaceuticals. Through her innovative approach, she has contributed to advancements in biotechnology and cellular research.

Latest Patents

Melanie Briegel holds a notable patent for her invention titled "Method for Increasing Recloning Efficiency." This patent addresses critical methods for replicating and cloning cells, particularly those used in biopharmaceutical production. The invention outlines techniques for preparing proteins utilizing cells obtained and replicated through single cell deposition. By incorporating Insulin-like Growth Factor (IGF) along with Human Serum Albumin (HSA) in the culture medium, her method significantly enhances recloning efficiency, resulting in a greater quantity of clones.

Career Highlights

Currently, Melanie Briegel is affiliated with Boehringer Ingelheim Pharma GmbH & Co. KG, a company recognized for its commitment to innovation in healthcare. Her work plays a pivotal role in advancing biopharmaceutical processes, which are essential for developing treatments and therapies that improve patient outcomes.

Collaborations

Throughout her career, Briegel has worked alongside talented colleagues such as Jüergen Fieder and Lore Florin. These collaborations foster a dynamic environment where innovative ideas can flourish, leading to groundbreaking advancements in the biotechnology sector.

Conclusion

Melanie Briegel's dedication to improving recloning techniques in cell culture technology positions her as a key figure in biopharmaceutical innovation. Her groundbreaking patent is a testament to her commitment to enhancing research processes and contributing to the field of biotechnology. As she continues her work with Boehringer Ingelheim, her future endeavors are likely to yield even more remarkable advancements in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…